SAN DIEGO, April 03, 2017 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce it has received CE Mark approval for its Fantom drug-eluting bioresorbable coronary scaffold, which offers multiple and substantial performance advantages over first-generation scaffolds on the market today. Fantom is REVA’s […]
Coronary/Structural Heart
Essential Medical, Inc., Addressing the Rapidly Growing Large Bore Vascular Closure Market
MALVERN, Pennsylvania, April 3, 2017 /PRNewswire/ — Essential Medical, Inc., a privately held medical device company addressing the rapidly growing large bore vascular closure market, announced the publication of the MANTA CE marking study results in JACC Interventions titled: “Percutaneous Plug-Based Arteriotomy Closure Device for Large-Bore Access” (http://dx.doi.org/10.1016/j.jcin.2016.12.277). This first, […]
Headcount Balloons as Abiomed (ABMD) Opens Doors to Its New Massachusetts HQ
Abiomed Marks Grand Opening of Newly-Expanded Headquarters in Danvers, Massachusetts – Governor Baker joins heart recovery leader for grand opening of new manufacturing and training space that represents major investment in Massachusetts DANVERS, Mass., March 30, 2017 (GLOBE NEWSWIRE) — Massachusetts Governor Charlie Baker today joined Abiomed – a leading […]
Cardiovascular Systems Snags FDA Nod for Its Diamondback 360 Coronary Orbital Atherectomy System (OAS)
Cardiovascular Systems, Inc. Receives Approval for the Diamondback 360® Coronary Orbital Atherectomy System (OAS) Micro Crown in the United States OAS Micro Crown Approved to Treat Severely Calcified Coronary Lesions Only Atherectomy Device Designed to Both Pilot Tight Lesions and Treat Up to 4mm Vessels with a Single Device ST. […]
Boston Scientific agrees to acquire Symetis
MARLBOROUGH, Mass., March 30, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices, for $435 million in up-front cash. The Symetis portfolio includes the ACURATE TA™ and ACURATE neo/TF valve* […]
Study Suggests Marijuana Use Can Bring a Greater Risk of Cardiovascular Disease
By Ken Dropiewski, Ken@Prime-Core.com According to LiveScience, a study conducted by the Einstein Medical Center in Philadelphia suggests that marijuana users have an increased risk of a number of cardiovascular diseases, including strokes and heart failure. The study did have some limited parameters, pointing to the need for more research. The […]
NEWS RELEASE Biosensors Announces Enrollment of the First American Patient in the new US Pivotal BioFreedom Trial – “LEADERS FREE II”
Press Release Singapore, 22 March 2017 – Biosensors International Group, Ltd. (“Biosensors” or the “Company”), a developer, manufacturer and marketer of innovative medical devices, announced today the enrollment of the first American patient in LEADERS FREE II, its new BioFreedom Pivotal Study, conducted under an Investigational Device Exemption (IDE), which […]
New Meta-Analysis Presented at American College of Cardiology Strongly Supports RenalGuard(R) Use in Cardiovascular Interventional Procedures
MILFORD, MA — (Marketwired) — 03/22/17 — A new meta-analysis presented this week at the American College of Cardiology further supports the ability of RenalGuard Therapy® to significantly reduce the incidence of acute kidney injury associated with cardiovascular interventional procedures compared to other methods of urine volume expansion. Moreover, findings […]
Tryton Medical Announces First U.S. Commercial Case with Tryton Side Branch Stent
DURHAM, N.C.–(BUSINESS WIRE)– Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that the first U.S. commercial case using the Tryton Side Branch Stent to treat a coronary bifurcation lesion involving a large side branch (appropriate for a ≥2.5mm stent) was completed at […]
BioStable Science & Engineering Wins FDA Nod for Its HAART 300 Aortic Annuloplasty Device
BioStable Science & Engineering Announces FDA Clearance of the HAART™ 300 Aortic Annuloplasty Device AUSTIN, Texas–(BUSINESS WIRE)–BioStable Science & Engineering, Inc. announced today it has received FDA market clearance for the HAART 300 Aortic Annuloplasty Device, the first commercially available internal annuloplasty device designed for aortic valve repair. BioStable expects […]